Bone growth during daily or intermittent calcitriol treatment during renal failure with advanced secondary hyperparathyroidism

Kidney International

Volumn 72, Issue 5, 2007, Pages 582-591

  Sanchez, C P ^a   He, Y Z ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bone growth; Calcitriol; Growth plate; Secondary hyperparathyroidism

Indexed keywords

CALCITRIOL; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; P21 ACTIVATED KINASE; PARATHYROID HORMONE; PROTEIN P57; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE GROWTH; CALCIUM BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SECONDARY HYPERPARATHYROIDISM;

ANIMALS; ANIMALS, SUCKLING; BONE DEVELOPMENT; CALCITRIOL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROCYTES; GROWTH; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RATS; RECEPTORS, PARATHYROID HORMONE;

EID: 34548147945     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002375     Document Type: Article

References (40)

1. Ardissino G, Schmitt CP, Testa S et al. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. Pediatr Nephrol 2000; 14: 664-668.
2. Schmitt CP, Ardissino G, Testa S et al. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 2003; 18: 440-444.
3. Salusky IB, Kuizon BD, Belin TR et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 1998; 54: 907-914.
4. Mehls O, Knoller N, Oh J et al. Daily but not pulse calcitriol therapy improves growth in experimental uremia. Pediatr Nephrol 2000; 14: 658-663.
5. 3 effects in primary cultures of growth cartilage cells of the rat. Calcif Tissue Int 1991; 49: 340-348.
6. 3 on matrix and DNA synthesis in condylar cartilage of suckling mice. Calcif Tissue Int 1987; 41: 95-104.
7. Mehls O, Ritz E, Hunziker EB et al. Improvement of growth and food utilization by human recombinant human growth hormone in uremia. Kidney Int 1988; 33: 45-52.
8. 1 progression, and cytokinesis. Genes Dev 2003; 17: 2465-2479.
9. Sanchez CP, Salusky IB, Kuizon BD et al. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int 1998; 54: 1879-1887.
10. 2+-sensing receptor activation in the growth plate. FASEB J 2004; 18: 143-145.
11. 3-induced growth inhibition of human prostate cancer cells. Prostate 2005; 64: 9-19.
12. Donkelaar Cv, Janssen X, Jong Ad. Distinct developmental changes in the distribution of calcium, phosphorus and sulphur during fetal growth-plate development. J Anat 2007; 210: 186-194.
13. Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci USA 2005; 102: 9637-9642.
14. Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 2004; 34: 26-36.
15. Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-4389.
16. Kiviranta R, Morko J, Alatalo S et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 2005; 36: 159-172.
17. Fazzalari N, Kuliwaba J, Atkins G et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaβ ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone MIner Res 2001; 16: 1015-1027.
18. Plachot JJ, Bois MBD, Halpern S et al. In vitro action of 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol on matrix organization and mineral ditribution in rabbit growth plate. Metab Bone Dis Rel Res 1982; 4: 135-142.
19. Sanchez C, He Y, Leiferman E, Wilsman N. Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism. Kidney Int 2004; 65: 1740-1748.
20. Kip2 mediates proliferative actions of PTHrP in chondrocytes. J Clin Invest 2004; 113: 1334-1343.
21. Guo J, Chung U, Yang D et al. PTH/PTHrP receptor delays chondrocyte hypertrophy via both Runx2-dependent and -independent pathways. Dev Biol 2006; 292: 116-128.
22. Waga S, Hannon G, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
23. KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA 1998; 95: 1392-1397.
24. 1 expression. Mol Biol Cell 2001; 12: 3852-3863.
25. Klaus G, Meinhold-Heerlein R, Milde P et al. Effect of vitamin D on growth cartilage cell proliferation in vitro. Pediatr Nephrol 1991; 5: 461-466.
26. 3 on the Expression of DNA Replication Genes. J Bone Miner Res 2004; 19: 133-146.
27. 1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 1998; 142: 57-65.
28. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142-153.
29. 3 receptor. Nucl Acids Res 2006; 34: 543-554.
30. 1 integrin in matrix interactions and proliferation of chondrocytes. J Bone Miner Res 1997; 12: 1124-1132.
31. 2+-sensing receptor in growth plate chondrocytes. Endocrinology 2005; 146: 294-303.
32. Sanchez CP, Kuizon BD, Abdella PA et al. Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure. Endocrinology 2000; 141: 1536-1544.
33. 3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549.
34. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for Vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315.
35. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095.
36. Thomas GP, Baker SU, Eisman JA, Gardiner EM. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol 2001; 170: 451-460.
37. Hofbauer LC, Khosla S, Dunstan CR et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12.
38. 3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 2003; 89: 771-777.
39. Wang Y, Nishida S, Elalieh HZ et al. Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 2006; 21: 1350-1358.
40. Sanchez CP, He Y-Z. Alterations in the growth plate cartilage of rats with renal failure receiving corticosteroid therapy. Bone 2002; 30: 692-698.